Summary
A specific hemorheologic treatment might reduce urinary protein excretion and the decline in kidney function in diabetic patients with overt clinical nephropathy. Twenty-one insulin dependent (type I) diabetic patients were randomized and assigned to a treatment with conventional antihypertensive therapy (protocol I) or with pentoxifylline (Trental 400®) (protocol II). A marked improvement of blood rheology pattern, together with a reduction of urinary albumin excretion rate and total urinary protein excretion rate, was demonstrated throughout a 1-year follow-up study with pentoxifylline. Furthermore a decrease of systolic and diastolic blood pressure levels was found during the treatment. The modification of these parameters was followed by a significant increase of creatinine clearance in each of the patients studied. The results obtained during pentoxifylline therapy were comparable to those obtained in patients treated with conventional antihypertensive drugs. Pentoxifylline may therefore be used in the treatment of advanced nephropathy in diabetic patients.
Similar content being viewed by others
References
Aprile C., Saponaro R., Solerte S. B.: Determination of glomerular filtration rate by Gates' method—J. nucl. Med.27, 1644, 1986.
Armitage P.: Statistical methods in medical research. Blackwell Sci. Publ., Oxford-Edinburgh, 1971.
Bradford M. M.: A rapid and sensitive method for the quantitation of microgram quantitaties of protein utilizing the principle of protein dye binding—Analyt. Biochem.72, 248, 1976.
Cordaro C., Carandente O.: Esperienze pratiche sulla metodica di filtrazione eritrocitaria— La Ricerca Clin. Lab.10 (Suppl. 1), 113, 1980.
Di Perri T., Guerrini M.: Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication—Angiology30, 40, 1983.
Ferrari E., Fioravanti M., Patti A. L., Viola C., Solerte S. B.: Effects of a long-term treatment (4-years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients—Pharmatherapeutica (in press).
Gates G. F.: Glomerular filtration rate: estimation from fractional renal accumulation of 99 mTc-DTPA (stannous)—Amer J. Radiol.138, 565, 1982.
Guerrini M., Pecchi S., Rossi A., Cappelli R., Pieragalli D., Acciavatti A.: Effect of pentoxifylline on blood hyperviscosity and peripheral haemodynamics in patients with peripheral obliterating arterial disease—Pharmatherapeutica3 (Suppl. 1), 52, 1983.
Laurell C.: Quantitative estimation of protein by electrophoresis in agarose gel containing antibodies—Analyt. Biochem.15, 45, 1966.
Letcher R. L., Chien S., Pickering T. G., Sealey J. E., Laragh J. H.: Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects—Amer. J. Med.70, 1195, 1981.
Mancini G., Carbonara A. O., Heremans J. F.: Immunochemical quantitation of antigens by single radial immunodiffusion—Immunochemistry2, 235, 1965.
Mogensen C. E.: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment—Scand. J. clin. Lab. Invest.36, 383, 1976.
Mogensen C. E., Christensen C. K., Vittinghus E.: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy—Diabetes32 (Suppl. 2), 64, 1983.
Muggeo M., Calabrò A., Businaro V., Patussi L., Volpe A., Signorini G. P., Crepaldi G.: Blood clotting, fibrinolytic and haemorheological parameters in ischaemic vascular disease: the effects of pentoxifylline in the treatment of acute cerebral vascular disease—Pharmatherapeutica3 (Suppl. 1), 74, 1983.
Müller R., Lehrach F.: Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline—Pharmatherapeutica2, 372, 1980.
Parving H-H., Andersen A. R., Smidt U. M., Svendsen P.Aa.: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy—Lanceti, 1175, 1983.
Pozza G., Cordaro C., Carandente O., Margonato A.: Studio sul rapporto tra filtrazione eritrocitaria ed altri fattori di rischio nell'angiopatia diabetica—La Ricerca Clin. Lab.11 (Suppl. 1), 317, 1981.
Satewachin I. I., Ilijn V. N., Schestaka V. A., Alexandrova N. P., Rodionov S. V., Danilova L. M., Ilijn S. G.: The use of pentoxifylline in a combined regimen for the prevention of rethrombosis in major blood vessels—Pharmatherapeutica2, 109, 1978.
Simpson L. O.: A hypothesis proposing increased blood viscosity as a cause of proteinuria and increased vascular permeability—Nephron31, 89, 1982.
Simpson L. O.: Intrinsic stiffening of red blood cells as the fundamental cause of diabetic nephropathy and microangiopathy—Nephron39, 344, 1985.
Solerte S. B., Adamo S., Viola C., Carnevale Schianca G. P., Crippa A., Cozzi A., Ferrari E.: Modificazioni emoreologiche e proteinuria nel diabete mellito complicato—G. ital. Diabetol.4, 245, 1984.
Solerte S. B., Adamo S., Viola C., Zambianchi E., Ferrari E.: Pentossifillina ed arteriosa nel diabete mellito: risultati a lungo termine in gruppi randomizzati. In:Pozza G., Carandente O. (Eds): Emoreologia in laboratorio ed in clinica—La Ricerca Clin. Lab.15, (Suppl. 1), 515, 1985.
Solerte S. B., Aprile C., Adamo S., Saponaro R., Carena M., Ferrari E. Blood viscosity and glomerular filtration rate in diabetes mellitus—Clin. Hemorheol.5, 693, 1985.
Solerte S. B., Aprile C., Fioravanti M., Viola C., Bacchella L., Zanoletti M., Patti A. L., Ferrari E.: Decreased renal plasma flow, blood hyperviscosity and plasma protein changes in type 1 (insulin-dependent) diabetics with overt nephropathy—Transplant. Proc.18, 1641, 1986.
Solerte S. B., Carnevale Schianca G. P., Adamo S., Viola C., Baldi S., Sgarro V., Ferrari E.: Diabetic microangiopathy: preventive therapeutical approach with pentoxifylline—Clin. Hemorheol.3, 290, 1983.
Solerte S. B., Carnevale Schianca G. P., Canepari C., Baldi F., Adamo S., Viola C., Ferrari E.: Erythrocyte deformability and its correlation with plasma protein changes and glycosylated haemoglobin in complicated diabetes mellitus—Diabetologia23, 304, 1982; abstract # 73.
Solerte S. B., Carnevale Schianca G. P., Viola C., Adamo S., Cozzi A., Crippa A., Ferrari E.: Pathogenetic mechanism of haemorheological factors in development and progression of diabetic nephropathy—Clin. Hemorheol.3, 327, 1983.
Solerte S. B., Ferrari E.: Diabetic retinal vascular complications and erythrocyte filtrability: results of a 2-year follow-up study with pentoxifylline—Pharmatherapeutica4, 341, 1985.
Solerte S. B., Fioravanti M., Aprile C., Patti A. L., Viola C., Saponaro R., De Rocco O., Schifino N., Zanoletti M., Bacchella L., Ferrari E.: Iperviscosità ematica e iperfiltrazione glomerulare in pazienti con diabete mellito insulino-dipendente di recente diagnosi—G. ital. Diabetol.6, 459, 1986.
Solerte S. B., Fioravanti M., Bozzetti A., Schifino N., Patti A. L., Fedele P., Viola C., Ferrari E.: Pentoxifylline, albumin excretion rate and proteinuria in type 1 and type 2 diabetic patients with microproteinuria. Results of a short-term randomized study—Acta diabetol. lat.23, 171, 1986.
Solerte S. B., Fioravanti M., Patti A. L., Zanoletti M. G., Schifino N., Mancin D., Zambianchi E., Aprile C., Ferrari E.: Variazioni dei livelli di fattore von Willebrand antigene e della fibronectina plasmatica in pazienti diabetici con iperfiltrazione glomerulare —G. ital. Diabetol. (in press).
Solerte S. B., Piovella F., Viola C., Carnevale Schianca G. P., Gamba G., Fioravanti M., Ferrari E.: Plasma fibronectin, von Willebrand factor antigen, and blood rheology. Association with diabetic microvascular disease—Acta diabetol. lat.22, 239, 1985.
Solerte S. B., Viola C., Adamo S., Carnevale Schianca G. P., Dalzano M., Ferrari E.: Proteinuria, microalbuminuria ed iperviscosità nel diabete mellito insulino-dipendente (tipo I). In:Pozza G., Carandente O. (Eds): Emoreologia in laboratorio ed in clinica—La Ricerca Clin. Lab.15 (Suppl. 1), 383, 1985.
Solerte S. B., Viola C., Adamo S., Carnevale Schianca G. P., Dalzano M., Ferrari E.: A xanthine derivative, pentoxifylline, in the treatment of diabetic nephropathy—Diabetes Res. (Suppl. 1), 526, 1985.
Solerte S. B., Viola C., Adamo S., Dalzano M., Carnevale Schianca G. P., Ferrari E.: Ipertensione arteriosa, iperviscosità e proteinuria nel diabete mellito insulino-dipendente di lunga durata. In:Pozza G., Carandente O. (Eds): Emoreologia in laboratorio ed in clinical— La Ricerca Clin. Lab.15 (Suppl. 1), 389, 1985.
Solerte S. B., Viola C., Bozzetti A., Adamo S., Di Santi M., Fioravanti M., Ferrari E.: Ipertensione arteriosa, iperviscosità ematica e complicanze microangiopatiche nel diabete mellito non insulino dipendente (tipo 2)—G. ital. Diabetol.5, 373, 1985.
Strano A., Davi G., Novo S., Avellone G., Pinto A.: Clinical evaluation of the effects of pentoxifylline in patients with chronic peripheral circulatory disorders—Pharmatherapeutica3 (Suppl. 1), 117, 1983.
Viberti G. C., Keen H.: The patterns of proteinuria in diabetes mellitus. Relevance to pathogenesis and prevention of diabetic nephropathy—Diabetes33, 686, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Solerte, S.B., Fioravanti, M., Patti, A.L. et al. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta diabet. lat 24, 229–239 (1987). https://doi.org/10.1007/BF02732042
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02732042